Ravi Salgia

New England Journal of Medicine · 2009–2020

A researcher in the Science corpus: 8 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Ravi Salgia's perspective

Ordered by how strongly the researchers Ravi Salgia trusts endorse each paper. Same corpus, a different order for every researcher.

1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
4. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
5. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
6. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
7. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
8. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (New England Journal of Medicine)
9. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)
10. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)

Their papers

• Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020) — 658 citations
• Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018) — 1,141 citations
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. (2015) — 714 citations
• Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer (2014) — 1,377 citations
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study (2012) — 1,243 citations
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011) — 898 citations
• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (2010) — 4,132 citations
• Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis (2009) — 789 citations